Single-agent Erlotinib vs Oral Etoposide in Paediatric Ependymoma

• Research type

  Research Study

• Full title

  A Randomised, Phase 2 Study of Single-agent Erlotinib verses Oral Etoposide in Patients with Recurrent or Refractory Paediatric Ependymoma

• IRAS ID

  44172

• Contact name

  Stergios Zacharoulis

• Sponsor organisation

  OSI Pharmaceuticals Inc

• Eudract number

  2009-016836-11

• Clinicaltrials.gov Identifier

  NCT01032070

• Research summary

  Ependymoma is the third most common central nervous system tumour type in children. There are few options for treatment of these tumours and the role of chemotherapy remains unclear. The PETEY (Paediatric Erlotinib Trial in Ependymoma) study is looking at the objective response rate (the number of patients demonstrating a complete or partial response) of the study drug, single agent erlotinib, versus oral etoposide, a commonly used treatment in this indication. Patients will be randomly assigned to one of the treatment arms. The medications will be given in cycles of 28 days until disease progression, death, intolerable toxicity, Investigator decision or patient/parent request. A total of 40 patients will be entered into this study from centres in the UK, United States of America and Canada.

• REC name

  London - Hampstead Research Ethics Committee

• REC reference

  11/H0720/8

• Date of REC Opinion

  26 Apr 2011

• REC opinion

  Further Information Favourable Opinion